S.E.E.D. Planning Group LLC Has $5.92 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

S.E.E.D. Planning Group LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% in the 1st quarter, HoldingsChannel reports. The firm owned 10,178 shares of the medical research company’s stock after acquiring an additional 371 shares during the quarter. Thermo Fisher Scientific makes up 2.2% of S.E.E.D. Planning Group LLC’s portfolio, making the stock its 19th biggest position. S.E.E.D. Planning Group LLC’s holdings in Thermo Fisher Scientific were worth $5,916,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. WCM Investment Management LLC increased its position in shares of Thermo Fisher Scientific by 0.3% during the fourth quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock worth $527,524,000 after acquiring an additional 2,928 shares in the last quarter. Summa Corp. purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $418,000. Phoenix Holdings Ltd. boosted its holdings in Thermo Fisher Scientific by 21.4% during the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after purchasing an additional 1,654 shares during the last quarter. S. R. Schill & Associates boosted its holdings in Thermo Fisher Scientific by 106.3% during the fourth quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock worth $816,000 after purchasing an additional 792 shares during the last quarter. Finally, Tsfg LLC boosted its holdings in Thermo Fisher Scientific by 8.3% during the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock worth $132,000 after purchasing an additional 19 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Up 0.4 %

TMO traded up $2.22 during trading on Friday, hitting $553.00. 6,150,885 shares of the stock traded hands, compared to its average volume of 1,473,906. The firm has a 50-day moving average of $574.84 and a 200 day moving average of $562.59. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The firm has a market capitalization of $211.09 billion, a P/E ratio of 35.45, a price-to-earnings-growth ratio of 2.57 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,873,516.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders sold 22,000 shares of company stock worth $12,532,780 over the last three months. 0.34% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on TMO shares. Jefferies Financial Group reiterated a “buy” rating and issued a $650.00 target price (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Barclays dropped their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday. Deutsche Bank Aktiengesellschaft upped their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Citigroup began coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Finally, HSBC increased their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $607.06.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.